About Us

Anatolia Geneworks was founded in 2010 in Istanbul by partners with over twenty years of expertise in molecular, genetics, health, mechanical engineering, and marketing. The company’s multidisciplinary structure plays a key role in developing solution-oriented and efficient goods for consumers all over the world. 

Its core area of expertise is in the design, development, and production of real-time PCR kits, nucleic acid extraction kits, quick antigen test kits, and Real-Time PCR equipment, as well as automatic nucleic acid extraction robots. It is one of the very few companies in the world that has the ability to create turnkey solutions for real-time PCR applications with the integration of these kits and device systems produced under the Anatolia Geneworks brand name. 

The company’s operations comply with the TS EN ISO 9001:2015 standard, the TS EN ISO 13485:2016 standard, the EU 2017/746 IVDR In Vitro Diagnostic Medical Device Regulation, the 98/79/EC IVD Directive, and the 2006/42/EC Machinery Directive for Full Quality Assurance Systems. 

Anatolia Geneworks has been authorized as an R&D Centre by the Ministry of Industry and Technology of the Republic of Türkiye in April 2017. As of October 21, 2021, Anatolia became a publicly listed company and began trading on the Istanbul Stock Exchange (BIST) under the ANGEN code. It has subsidiaries abroad in Italy, Pakistan, Netherlands, Bulgaria, Philippines, Poland and Germany. 

The company’s primary aims are to achieve worldwide market success by developing and manufacturing high-quality molecular genetic goods, as well as minimise Türkiye’s foreign dependency in the field of molecular diagnostics and biotechnology. Anatolia Geneworks manufactures kits in R&D and production laboratories with the most advanced infrastructure that meets the ISO 6 clean room standards. The company guarantees the high precision, linearity, consistency, performance, and quality of its products by stringent quality control methods in compliance with the criteria of the TS EN ISO 13485:2016 standard, and the 98/79/EC IVD Directive. The company’s works on the transition to the EU 2017/746 IVDR In Vitro Diagnostic Medical Devices Regulation continue.